Profile of pazopanib and its potential in the treatment of epithelial ovarian cancer

References

• International Agency for Research on CancerGlobocan 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012 – fact sheets by population Available from: http://globocan.iarc.fr/Pages/fact_sheets_population.aspxAccessed December 22, 2013
   Google Scholar
• OzolsRFBundyBNGreerBEPhase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group studyJ Clin Oncol200321173194320012860964
   PubMed Web of Science ®Google Scholar
• du BoisALuckHJMeierWA randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancerJ Natl Cancer Inst200395171320132912953086
   PubMed Web of Science ®Google Scholar
• ArmstrongDKBundyBWenzelLIntraperitoneal cisplatin and paclitaxel in ovarian cancerN Eng J Med200635413443
   PubMed Web of Science ®Google Scholar
• KatsumataNYasudaMIsonishiSLong-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trialLancet Oncol201314101020102623948349
   PubMed Web of Science ®Google Scholar
• BurgerRABradyMFBookmanMAIncorporation of bevacizumab in the primary treatment of ovarian cancerN Eng J Med20113652624732483
   PubMed Web of Science ®Google Scholar
• PerrenTJSwartAMPfistererJA phase 3 trial of bevacizumab in ovarian cancerN Eng J Med20113652624842496
   PubMed Web of Science ®Google Scholar
• BrowderTButterfeldCEKralingBMAntiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancerCancer Res20006071878188610766175
   PubMed Web of Science ®Google Scholar
• ColleoniMRoccaASandriMTLow-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levelsAnn Oncol2002131738011863115
   PubMed Web of Science ®Google Scholar
• LinderholmBKLidbrinkETallrothEAngiogenic factors in relation to clinical effect in a phase II trial of weekly paclitaxelBreast20132261142114723968864
   PubMed Web of Science ®Google Scholar
• FennellyDAghajanianCShapiroFPhase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancerJ Clin Oncol19971511871928996141
   PubMed Web of Science ®Google Scholar
• Clinicaltrials.gov Available at: clinicaltrials.govAccessibility verified January 31, 2014
   Google Scholar
• FIGO Committee on Gynecologic Oncology: Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasiaInt J Gynaecol Obstet200910513419322933
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer NetworkClinical practice guidelines in oncology: ovarian cancer including fallopian tube cancer and primary peritoneal cancer Available from: http://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdfAccessed December 22, 2013
   Google Scholar
• ChanJBradyMPensonRPhase III trial of every-3-weeks paclitaxel vs. dose dense weekly paclitaxel with carboplatin +/− bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262Oral presentation at: 18th European Society of Gynaecological Oncology International MeetingOctober 19–22, 2013Liverpool, UK
   Google Scholar
• MonkBJPovedaAVergoteIA phase III, randomized, double-blind trial of weekly paclitaxel plus the angiopoietin 1 and 2 inhibitor, trebananib, or placebo in women with recurrent ovarian cancer: TRINOVA-1Poster presented at: European Society for Medical Oncology Cancer CongressSeptember 27–October 1, 2013Amsterdam, Netherlands
   Google Scholar
• duBoisAFloquetAKimJRandomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (AEOC): results of an international Intergroup trial (AGO-OVAR16)Am Soc Clin Oncol201331SupplLBA5503
   Google Scholar
• LedermannJAPerrenTJRajaFARandomised double-blind phase III trial of cediranib (AZD 21717) in relapsed platinum sensitive ovarian cancer: results of the ICON6 trialPoster presented at: European Society for Medical Oncology Cancer CongressSeptember 27–October 1, 2013Amsterdam, Netherlands
   Google Scholar
• du BoisAVergoteIWimbergerPOpen-label feasibility study of pazopanib, carboplatin, and paclitaxel in women with newly diagnosed, untreated, gynaecologic tumours: a phase I/II trial of the AGO study groupBr J Cancer2012106462963222240783
   PubMed Web of Science ®Google Scholar
• WeidnerNSempleJPWelchWRFolkmanJTumor angiogenesis and metastasis – correlation in invasive breast carcinomaN Eng J Med1991324118
   PubMed Web of Science ®Google Scholar
• WeidnerNFolkmanJPozzaFTumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinomaJ Natl Cancer Inst19928424187518871281237
   PubMedGoogle Scholar
• WeidnerNCarrollPRFlaxJBlumenfeldWFolkmanJTumor angiogenesis correlates with metastasis in invasive prostate carcinomaAm J Pathol199314324014097688183
   PubMed Web of Science ®Google Scholar
• ZätterströmUKBrunEWillénRKjellénEWennerbergJTumor angiogenesis and prognosis in squamous cell carcinoma of the head and neckHead Neck19951743123187545656
   PubMed Web of Science ®Google Scholar
• de JongJSvan DiestPJBaakJPHot spot microvessel density and the mitotic activity index are strong additional prognostic indicators in invasive breast cancerHistopathology200036430631210759944
   PubMed Web of Science ®Google Scholar
• HlatkyLHahnfeldtPFolkmanJClinical application of antiangiogenic therapy: microvessel density, what it does and doesn’t tell usJ Natl Cancer Inst2002941288389312072542
   PubMedGoogle Scholar
• RubattJMDarcyKMHutsonAIndependent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: a Gynecologic Oncology Group studyGynecol Oncol2009112346947419135712
   PubMed Web of Science ®Google Scholar
• AlvarezAAKrigmanHRWhitakerRSDodgeRKRodriguezGCThe prognostic significance of angiogenesis in epithelial ovarian carcinomaClin Cancer Res19995358759110100710
   PubMed Web of Science ®Google Scholar
• RamakrishnanSSubramanianIVYokoyamaYGellerMAngiogenesis in normal and neoplastic ovariesAngiogenesis20058216918216211363
   PubMedGoogle Scholar
• BurgerRAOverview of anti-angiogenic agents in development for ovarian cancerGynecol Oncol2011121123023821215996
   PubMed Web of Science ®Google Scholar
• NagyJADvorakAMDvorakHFVEGF-A and the induction of pathological angiogenesisAnnu Rev Pathol2007225127518039100
   PubMed Web of Science ®Google Scholar
• GadducciAViacavaPCosioSVascular endothelial growth factor (VEGF) expression in primary tumors and peritoneal metastases from patients with advanced ovarian carcinomaAnticancer Res2003233C3001300812926153
   PubMed Web of Science ®Google Scholar
• ZebrowskiBKLiuWRamirezKAkagiYMillsGBEllisLMMarkedly elevated levels of vascular endothelial growth factor in malignant ascitesAnn Surg Oncol19996437337810379858
   PubMed Web of Science ®Google Scholar
• HambergPVerweijJSleijferS(Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitorOncologist201015653954720511320
   PubMed Web of Science ®Google Scholar
• LiLWangLZhangWCorrelation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancerAnticancer Res2004243b1973197915274387
   PubMed Web of Science ®Google Scholar
• WildRDingsRPSubramanianIRamakrishnanSCarboplatin selectively induces the VEGF stress response in endothelial cells: potentiation of antitumor activity by combination treatment with antibody to VEGFInt J Cancer2004110334335115095298
   PubMed Web of Science ®Google Scholar
• SteeleIAEdmondsonRJBulmerJNBolgerBSLeungHYDaviesBRInduction of FGF receptor 2-IIIb expression and response to its ligands in epithelial ovarian cancerOncogene200120415878588711593393
   PubMed Web of Science ®Google Scholar
• SallinenHHeikuraTLaidinenSPreoperative angiopoietin-2 serum levels: a marker of malignant potential in ovarian neoplasms and poor prognosis in epithelial ovarian cancerInt J Gynecol Cancer20102091498150521119365
   PubMed Web of Science ®Google Scholar
• HenriksenRFunaKWilanderEBäckströmTRidderheimMObergKExpression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasmsCancer Res19935319455045548402626
   PubMed Web of Science ®Google Scholar
• TsutsumiSIshibashiKUchidaNPhase II trial of chemotherapy plus bevacizumab as second-line therapy for patients with metastatic colorectal cancer that progressed on bevacizumab with chemotherapy: the Gunma Clinical Oncology Group (GCOG) trial 001 SILK studyOncology201283315115722889925
   PubMed Web of Science ®Google Scholar
• GrotheyASugrueMMPurdieDMBevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE)J Clin Oncol200826335326533418854571
   PubMed Web of Science ®Google Scholar
• McCannGASmithBBackesFJRecurrent ovarian cancer: is there a role for re-treatment with bevacizumab after an initial complete response to a bevacizumab-containing regimen?Gynecol Oncol2012127236236622885866
   PubMed Web of Science ®Google Scholar
• American Cancer SocietyPazopanib Available at: http://www.cancer.org/treatment/treatmentsandsideeffects/guidetocancerdrugs/pazopanibAccessed January 31, 2014
   Google Scholar
• KumarRKnickVBRudolphSKPharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activityMol Cancer Ther2007672012202117620431
   PubMed Web of Science ®Google Scholar
• BergersGSongSMeyer-MorseNBergslandEHanahanDBenefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitorsJ Clin Invest200311191287129512727920
   PubMed Web of Science ®Google Scholar
• MerrittWMNickAMCarrollARBridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancerMol Cancer Ther20109498599520371710
   PubMed Web of Science ®Google Scholar
• PodarKTononGSattlerMThe small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myelomaProc Natl Acad Sci U S A200610351194781948317164332
   PubMed Web of Science ®Google Scholar
• HarrisPABoloorACheungMDiscovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitorJ Med Chem200851154632464018620382
   PubMed Web of Science ®Google Scholar
• US Food and Drug AdministrationFDA approves new treatment for advanced form of kidney cancer [press release]Silver Spring, MDUS FDA2009 [October 19]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm187174.htmAccessed December 22, 2013
   Google Scholar
• US Food and Drug AdministrationFDA approves Votrient for advanced soft tissue sarcoma [press release]Silver Spring, MDUS FDA4262012 Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm302065.htmAccessed December 22, 2013
   Google Scholar
• HurwitzHIDowlatiASainiSPhase I trial of pazopanib in patients with advanced cancerClin Cancer Res200915124220422719509175
   PubMed Web of Science ®Google Scholar
• BurrisHA3rdDowlatiAMossRAPhase I study of pazopanib in combination with paclitaxel and carboplatin given every 21 days in patients with advanced solid tumorsMol Cancer Ther20121181820182822679111
   PubMed Web of Science ®Google Scholar
• TanARDowlatiAJonesSFPhase I study of pazopanib in combination with weekly paclitaxel in patients with advanced solid tumorsOncologist201015121253126121147873
   PubMed Web of Science ®Google Scholar
• de JongeMJHambergPVerweijJPhase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumorsInvest New Drugs201331375175923054212
   PubMed Web of Science ®Google Scholar
• KerklaanBMLolkemaMDevrieseLAPhase I study of safety, tolerability, and pharmacokinetics of pazopanib in combination with oral topotecan in patients with advanced solid tumorsJ Clin Oncol201331Suppl2536
   Google Scholar
• PlummerRMadiAJeffelsMA Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumorsCancer Chemother Pharmacol20137119310123064954
   PubMed Web of Science ®Google Scholar
• DuskaLRA Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer Available from: http://clinicaltrials.gov/show/NCT01610206. NLM identifier: NCT01610206Accessed: January 31, 2014
   Google Scholar
• NegrierSImbsDCPerolDPazopanib (P) and bevacizumab (B) in patients with metastatic renal cell carcinoma (mRCC) or other advanced refractory tumors: Phase I combination study final analysisJ Clin Oncol201331Suppl4574
   Google Scholar
• FriedlanderMHancockKCRischinDA Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancerGynecol Oncol20101191323720584542
   PubMed Web of Science ®Google Scholar
• Response Evaluation Criteria in Solid Tumors Available at: http://www.recist.comAccessibility verified: January 31, 2014
   Google Scholar
• OakninAGonzalez-MartinAGarciaYPhase II study of pazopanib in recurrent or persistent ovarian (EOC), peritoneal (PPC), or Fallopian tube cancer (FTC): a Spanish Ovarian Cancer Group (GEICO) studyJ Clin Oncol201230Suppl5068
   Google Scholar
• SehouliJPazopanib and weekly topotecan in patients recurrent ovarian cancer (TOPAZ) Available from: http://clinicaltrials.gov/ct2/show/NCT01600573?term=NCT01600573&rank=1. NLM identifier: NCT01600573Accessed January 31, 2014
   Google Scholar
• National Cancer Institute, NaplesWeekly paclitaxel with or without pazopanib in platinum resistant or refractory ovarian cancer (MITO-11) Available from: http://clinicaltrials.gov/ct2/show/NCT01644825?term=NCT01644825&rank=1. NLM identifier: NCT016448251312014
   Google Scholar
• SCRIDevelopmentInnovationsLLCStudy of pazopanib and doxil in patients with advanced relapsed platinum-sensitive or platinum-resistant ovarian, fallopian tube or primary peritoneal adenocarcinoma Available from: http://clinicaltrials.gov/ct2/show/NCT01035658?term=NCT01035658&rank=1. NLM identifier: NCT01035658Accessed January 31, 2014
   Google Scholar
• Cambridge University Hospitals NHS Foundation TrustHYPAZ: Hypertension induced by pazopanib Available from: http://clinicaltrials.gov/ct2/show/NCT01392352?term=NCT01392352&rank=1. NLM identifier: NCT01392352Accessed January 31, 2014
   Google Scholar
• EichbaumMMayerCEickhoffRThe PACOVAR-trial: a phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancerBMC Cancer20111145322014006
   PubMed Web of Science ®Google Scholar
• ZangRWuLZhuJPazopanib (Paz) monotherapy in Asian women who have not progressed after first-line chemotherapy for advanced ovarian, fallopian tube, or primary peritoneal carcinomaJ Clin Oncol201331Suppl5512
   Google Scholar
• GuoJJinJHuangYComparison of PFS and safety for Asian compared to North American and European populations in the phase III trial of pazopanib versus sunitinib in patients with treatment-naive RCC (COMPARZ)J Clin Oncol201331Suppl 6366
   Web of Science ®Google Scholar
• FriedlanderMKMeierWLesoinAQuality of life in patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (AEOC) receiving either pazopanib monotherapy or placebo after first-line chemotherapy: AGO-OVAR16 resultsPoster presented at: European Society for Medical Oncology Cancer CongressSeptember 27–October 1, 2013Amsterdam, the Netherlands
   Google Scholar
• SternbergCNHawkinsREWagstaffJA randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety updateEurJ Cancer20134961287129623321547
   PubMed Web of Science ®Google Scholar
• QiWXLinFSunYJIncidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysisCancer Chemother Pharmacol201371243143923178953
   PubMed Web of Science ®Google Scholar
• ShibataSIChungVSynoldTWPhase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group studyClin Cancer Res201319133631363923653147
   PubMed Web of Science ®Google Scholar
• SiderasKMenefeeMEBurtonJKErlichmanCBibleKCIvySPProfound hair and skin hypopigmentation in an African American woman treated with the multi-targeted tyrosine kinase inhibitor pazopanibJ Clin Oncol20102819e312e31320516434
   PubMed Web of Science ®Google Scholar
• SemradTJEddingsCDutiaMPChristensenSLaraPNJrPhase I study of the combination of temsirolimus and pazopanib in advanced solid tumorsAnticancer Drugs201324663664023698253
   PubMed Web of Science ®Google Scholar
• HincheyJChavesCAppignaniBA reversible posterior leukoencephalopathy syndromeN Eng J Med19963348494500
   PubMed Web of Science ®Google Scholar
• SchwartzRBJonesKMKalinaPHypertensive encephalopathy: findings on CT, MR imaging, and SPECT imaging in 14 casesAJR Am J Roentgenol199215923793831632361
   PubMed Web of Science ®Google Scholar
• StoneRLSoodAKColemanRLCollateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancerLancet Oncol201011546547520226736
   PubMed Web of Science ®Google Scholar
• RandallLMMonkBJBevacizumab toxicities and their management in ovarian cancerGynecol Oncol2010117349750420363017
   PubMed Web of Science ®Google Scholar
• HanESMonkBJWhat is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?Gynecol Oncol200710513617383545
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKlineInvestigator’s Brochure for Pazopanib (GW786034) for Oncology and Opthalmic Indications10th edBrentford, UKGlaxoSmithKline2013
   Google Scholar
• GohBCReddyNJDandamudiUBAn evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5+1 cocktail in patients with advanced solid tumorsClin Pharm Ther2010885652659
   PubMed Web of Science ®Google Scholar
• XuCFXueZBingNConcomitant use of pazopanib and simvastatin increases the risk of transaminase elevations in patients with cancerAnn Oncol20122392470247122918879
   PubMed Web of Science ®Google Scholar
• TranHTLiuYZuritaAJPrognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trialsLancet Oncol201213882783722759480
   PubMed Web of Science ®Google Scholar
• GoedeVCoutelleONeuneierJIdentification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapyBr J Cancer201010391407141420924372
   PubMed Web of Science ®Google Scholar
• NixonABPangHStarrMDPrognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB 80303 (Alliance)Clin Cancer Res201319246957696624097873
   PubMed Web of Science ®Google Scholar
• Imperial College London[18F]Fluciclatide-PET, pazopanib and paclitaxel in ovarian cancer (PAZPET-1) Available from: http://clinicaltrials.gov/ct2/show/NCT01608009?term=NCT01608009&rank=1. NLM identifier: NCT01608009Accessed January 31, 2014
   Google Scholar
• European Organisation for Research and Treatment of Cancer - EORTCPazopanib hydrochloride, paclitaxel, and carboplatin in treating patients with refractory or resistant ovarian epithelial cancer, fallopian tube cancer, or peritoneal cancer Available from: http://clinicaltrials.gov/ct2/show/NCT01402271?term=NCT01402271&rank=1. NLM identifier: NCT01402271Accessed January 31, 2014
   Google Scholar
• GrandeECasanovasOEarlJsVEGFR2 and circulating tumor cells to predict for the efficacy of pazopanib in neuroendocrine tumors (NETs): PAZONET subgroup analysisJ Clin Oncol201331Suppl414024081945
   PubMed Web of Science ®Google Scholar
• NecchiAMarianiLZaffaroniNPazopanib in advanced and platinum resistant urothelial cancer: an open-label, single group phase 2 trialLancet Oncol201213881081622819172
   PubMed Web of Science ®Google Scholar
• KattanMWChakrabartiDBhattKMehmudFSternbergCNMotzerRJDevelopment and internal validation of a prognostic nomogram for overall survival in patients with advanced renal cell carcinoma (aRCC) treated with pazopanib (PAZ)J Clin Oncol201331638023233708
   PubMed Web of Science ®Google Scholar
• DyGKInfanteJREckhardtSGPhase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with erlotinibInvest New Drugs201331489189923135778
   PubMed Web of Science ®Google Scholar
• FasoloASessaCBauerJAPhase Ib clinical and pharmacological study of multiple schedules of pazopanib and epirubicin in patients with advanced solid tumorsPresented at: 2010 American Society of Clinical Oncology Annual Meeting4–8, JuneChicago, IL
   Google Scholar